John C. Martin (businessman)

John C. Martin
Born	1951 Easton, Pennsylvania
Nationality	American
Institutions	Gilead Sciences
Alma mater	Purdue University, Golden Gate University, University of Chicago
Known for	Antiviral therapeutics
Notable awards	Biotechnology Heritage Award (2017)

John C. Martin (born 1951) is the executive chairman (2016-) and former CEO (1996-2016) of the American biotechnology company Gilead Sciences. He joined Gilead Sciences in 1990 as Vice President for Research and Development. In addition to helping developing other drugs such as Atripla (for HIV/AIDS), Martin led the team that developed Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. He is the recipient of a number of awards, including the Biotechnology Heritage Award (2017).

Martin earned his BS in chemical engineering from Purdue University, an MBA in marketing from Golden Gate University and a PhD in organic chemistry from the University of Chicago. He serves on the Board of Trustees of the latter two universities.

Martin focuses on the development of antiviral therapeutics. He has helped to develop drugs including ganciclovir, cidofovir, oseltamivir, adefovir, tenofovir, didanosine, stavudine, tenofovir, emtricitabine, Truvada, Atripla, Complera, Stribild and Sofosbuvir.

Martin worked at Syntex Corporation from 1978 to 1984.

...
Wikipedia